drugset
drugset / Trial / NCT04729309

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

NCT04729309 ↗

Phase 1 Completed 22 enrolled Hoffmann-La Roche
Non-randomizedParallel-groupOpen-labelOther

Summary

The objective of this study is to characterize the mass balance, absolute bioavailability, route and rates of elimination of RO7049839.

Timeline

Start
2021-03-31
Primary completion
2021-06-14
Completion
2021-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject LINVENCORVIR Small molecule — Oral

Indications

No indication recorded.